Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J. Weisdorf D, et al. Among authors: curtsinger j. Biol Blood Marrow Transplant. 2012 Jun;18(6):937-43. doi: 10.1016/j.bbmt.2011.11.024. Epub 2011 Dec 7. Biol Blood Marrow Transplant. 2012. PMID: 22155505 Free PMC article. Clinical Trial.
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Bachanova V, et al. Among authors: curtsinger j. Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9. Blood. 2014. PMID: 24719405 Free PMC article. Clinical Trial.
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.
Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Miller JS, et al. Among authors: curtsinger j. Biol Blood Marrow Transplant. 2014 Aug;20(8):1252-7. doi: 10.1016/j.bbmt.2014.05.004. Epub 2014 May 9. Biol Blood Marrow Transplant. 2014. PMID: 24816582 Free PMC article.
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.
Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE. Brunstein CG, et al. Among authors: curtsinger j. Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12. Blood. 2016. PMID: 26563133 Free PMC article. Clinical Trial.
Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.
de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS. de Witte MA, et al. Among authors: curtsinger j. Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162. doi: 10.1016/j.bbmt.2018.02.023. Epub 2018 Mar 2. Biol Blood Marrow Transplant. 2018. PMID: 29505821 Free PMC article.
141 results